Gamma rays treat cancer by delivering concentrated, high-energy radiation that breaks apart the DNA inside tumor cells, making it impossible for them to divide and survive. The most well-known application is a device called the Gamma Knife, which aims up to 192 individual beams of gamma radiation from cobalt-60 sources at a single point inside the brain, destroying tumors without a scalpel ever touching the skull. But gamma rays also play roles in other forms of radiation therapy and in newer systemic treatments that send radioactive molecules through the bloodstream to hunt down cancer cells wherever they hide. The technology has been refined over decades, and the ways it intersects with immunotherapy and artificial intelligence are shifting what doctors can offer patients today.
How Gamma Rays Destroy Tumor Cells
Gamma rays are a form of ionizing radiation, meaning they carry enough energy to knock electrons out of atoms. When a gamma ray passes through living tissue, it can damage cells in two ways. The first is direct: the radiation strikes DNA and physically severs the molecular strands. The second, and more common route, is indirect: the gamma ray hits a water molecule inside the cell, which generates highly reactive fragments called free radicals. Those free radicals then collide with nearby DNA and break its chemical bonds within fractions of a second.1International Journal of Radiology and Radiation Oncology. The impact of Gamma Ray on DNA molecule
A single strand break in DNA is usually repairable; cells have built-in machinery for patching that kind of damage. A double-strand break, where both rails of the DNA ladder snap at roughly the same spot, is far more dangerous. Cells that accumulate enough double-strand breaks lose the ability to copy themselves accurately. They either die outright or trigger their own self-destruct program. Cancer treatment with gamma rays is designed to inflict enough of those lethal double-strand breaks on tumor cells while giving surrounding healthy tissue the best possible chance to repair itself.
Whether radiation succeeds or fails against a given tumor depends on several biological factors: how well the cancer cells repair DNA damage, where they are in their growth cycle at the moment of irradiation, how quickly surviving cells repopulate, and whether the tumor’s interior has enough oxygen for the free-radical chemistry to work efficiently.2PubMed Central. Radiation resistance of cancer stem cells: the 4 R’s of radiobiology revisited Oxygen matters because free radicals need it to “fix” damage in place, preventing the DNA from snapping back together. Many solid tumors have chaotic, poorly formed blood vessels that leave patches of tissue starved for oxygen, and those oxygen-poor zones tend to resist radiation.3PubMed Central. A Review of the Role of Hypoxia in Radioresistance in Cancer Therapy Doctors account for these biological realities when choosing the radiation dose, the number of treatment sessions, and the timing between them.
The Gamma Knife and How It Works
The Gamma Knife is the flagship technology for using gamma rays against brain tumors and other intracranial targets. Developed by Swedish neurosurgeon Lars Leksell, it was designed to treat lesions inside the skull without opening it.4PubMed. The history of stereotactic radiosurgery and radiotherapy Despite its name, it involves no blade. Instead, it uses a hemispherical array of cobalt-60 radioactive sources, each producing a narrow beam of gamma rays. Those beams all converge on a single point, the way spokes of a wheel converge at the hub.5International Journal of Radiation Oncology*Biology*Physics. Physics of gamma knife approach on convergent beams in stereotactic radiosurgery
Each individual beam is too weak to cause meaningful harm as it passes through healthy brain tissue. But where all the beams cross, the radiation doses add up to a lethal concentration. The result is an extremely focused zone of high radiation surrounded by a steep drop-off, meaning tissue just millimeters away from the target receives a dramatically lower dose. Modern Gamma Knife systems achieve sub-millimeter positioning accuracy, with one study measuring average positioning uncertainty at just 0.03 millimeters.6PubMed. Quality assurance of stereotactic alignment and patient positioning mechanical accuracy for robotized Gamma Knife radiosurgery That precision is what allows the device to irradiate a tumor sitting next to critical structures like the optic nerve or brainstem without destroying them.
What Treatment Day Looks Like
Gamma Knife treatment is typically done on an outpatient basis, with the entire process from setup to completion often fitting within a single day. But “outpatient” does not mean casual. The experience involves several distinct phases, and what patients find most memorable is usually the immobilization step.
Traditionally, the patient’s head is secured to a rigid metal stereotactic frame using small pins that press against the skull under local anesthesia. The frame provides a coordinate system so the treatment team can map the exact tumor location. Then the patient undergoes imaging, usually an MRI, with the frame in place. Physicists and physicians use the images to design a plan that shapes the radiation dose to fit the tumor’s three-dimensional contours.
Newer Gamma Knife models offer a mask-based alternative. A thermoplastic mask molds to the patient’s face and holds the head steady without pins. In patient surveys comparing the two approaches, pain was the most common complaint about the frame, while claustrophobia and worry about holding still were the top concerns with the mask.7PubMed. Patient perspectives on frame versus mask immobilization for gamma knife stereotactic radiosurgery In one comparison, roughly half of frame-based patients found the procedure uncomfortable, whereas about 91% of mask-based patients did not.8Neuro-Oncology. RTHP-03. FRAME-BASED AND MASKED STEREOTACTIC RADIOSURGERY: A PATIENT EXPERIENCE COMPARISON WITH THE GAMMA KNIFE ICON The mask approach also opens the door to multi-session treatments, where the total dose is split across two or more visits rather than delivered all at once.
Splitting the dose into sessions can reduce the risk of damage to nearby healthy brain tissue. A study of patients with meningiomas found that multi-session delivery significantly lowered the probability of normal-tissue complications compared to single-session treatment, while tumor control remained similar between the two approaches.9Wasit Journal for Pure sciences. Cobalt-60 Nuclear Source Decay and Gamma Photon Dose Delivery in Radiosurgery: A Radiobiological Comparison of Single- and Multi-Session Irradiation for meningioma In practice, whether you get one session or several depends on the tumor’s size, location, and proximity to sensitive structures.
Which Conditions Gamma Knife Radiosurgery Treats
Gamma Knife radiosurgery was originally conceived for brain conditions, and that remains its primary territory. The list of targets has expanded considerably since its early days:
- Brain metastases: Cancers that started in the lung, breast, skin, or elsewhere and spread to the brain are among the most common Gamma Knife targets. The tight dose falloff allows doctors to treat multiple small metastases in one session without bathing the whole brain in radiation.
- Meningiomas: These typically slow-growing tumors arising from the brain’s lining are well suited to radiosurgery because of their defined borders and predictable biology.
- Acoustic neuromas (vestibular schwannomas): These benign tumors on the hearing and balance nerve grow near facial nerves and the brainstem. Gamma Knife radiosurgery provides high local control while being more likely to preserve hearing and facial nerve function compared to open surgery.10Romanian Neurosurgery. GAMMA-KNIFE RADIOSURGERY IN ACOUSTIC NEUROMA Typical prescription doses range from about 12 to 13 Gy at the tumor margin for current protocols, though earlier studies used 16 to 20 Gy.11PubMed. Stereotactic radiosurgery using the gamma knife for acoustic neuromas
- Pituitary adenomas: Hormone-secreting or vision-threatening pituitary tumors can be controlled with a single radiosurgery session when surgery is too risky or incomplete.
- Arteriovenous malformations: These tangles of abnormal blood vessels in the brain are not cancer, but Gamma Knife radiation can gradually close them off, reducing the risk of life-threatening bleeding.
- Trigeminal neuralgia: Severe facial pain caused by nerve irritation can be treated by targeting a small section of the trigeminal nerve with a focused gamma ray dose.
The common thread across these conditions is that the target is well-defined, sits inside the skull, and is either too small or too dangerously located for a conventional surgical approach to be the clear best option.
Side Effects and Risks
Gamma Knife radiosurgery is generally well tolerated compared to open brain surgery, but it is not risk-free. The most immediate side effects tend to be mild: headache at the pin sites (for frame-based treatment), nausea, and fatigue that typically resolves within a day or two.
The more serious risk is radiation necrosis, a condition where brain tissue at or near the treatment site dies and swells weeks to months after treatment. This swelling can mimic tumor regrowth on imaging and cause neurological symptoms depending on its location. In most cases, corticosteroids can manage the swelling. When steroids fail, a drug called bevacizumab, which blocks a protein involved in blood vessel growth and fluid leakage, has shown significant clinical and radiographic improvement.12PubMed. Bevacizumab for the Treatment of Gammaknife Radiosurgery-Induced Brain Radiation Necrosis In rare cases, radiation necrosis can cause severe brain edema requiring surgical intervention.13PubMed. Delayed radiation necrosis with extensive brain edema after gamma knife radiosurgery for multiple cerebral cavernous malformations–case report
There is also a long-term consideration: radiation-induced secondary cancers. Any radiation exposure carries a theoretical risk of causing a new malignancy years later. For Gamma Knife specifically, estimates of lifetime risk of radiation-induced malignancy from scattered radiation to the body range from roughly 0.03% to under 1% for patients treated between the ages of 5 and 45. That is considerably lower than the estimated risks from some other stereotactic platforms.14Meditsinskaya Fizika. Extracranial Dose and the Risk of Radiation-Induced Malignancy after Intracranial Stereotactic Radiosurgery: is it Time to Establish a Therapeutic Reference Level? For most patients, the benefit of treating a known brain tumor far outweighs this small added risk, but it is one reason doctors weigh alternatives carefully when treating young patients with benign conditions.
Cost Compared to Open Surgery
One of the practical advantages of Gamma Knife treatment over conventional brain surgery is cost. Because the procedure is done on an outpatient basis, it avoids the expense of operating rooms, anesthesia teams, intensive care stays, and extended hospitalization. A cost-effectiveness analysis of benign skull-base tumors found that the overall socioeconomic cost for open surgery was substantially higher than for Gamma Knife radiosurgery, and that the cost per quality-adjusted life year was roughly two and a half times lower with the Gamma Knife.15PubMed. Socioeconomic costs of open surgery and gamma knife radiosurgery for benign cranial base tumors Patients also lose fewer workdays and face fewer surgical complications.16PubMed Central. Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Cost-Effectiveness Results
That said, Gamma Knife units are expensive to install and maintain, and not every hospital has one. The cobalt-60 sources decay over time and must be replaced roughly every five to seven years, which represents a significant capital cost. These economic realities mean access can vary widely depending on where you live, and for some conditions, radiosurgery may not be available locally even when it would be the preferred approach.
Gamma Rays Beyond the Gamma Knife
The Gamma Knife gets most of the attention, but gamma rays enter cancer treatment through other channels. Conventional external-beam radiation therapy machines, called linear accelerators, produce high-energy X-rays that overlap in energy with gamma rays. The physics at the point of tissue interaction is essentially the same; the difference is in how the beams are generated and shaped. Some linear accelerators can deliver stereotactic treatments to the body, not just the brain, targeting lung, liver, spine, and other tumors with similar precision principles.
Then there is a completely different use of gamma radiation: systemic radiopharmaceutical therapy. In this approach, a radioactive atom is attached to a molecule that naturally seeks out a particular type of cancer cell. When the patient swallows or is injected with the compound, it circulates through the bloodstream, docks onto cancer cells wherever they are, and irradiates them from within. Radioiodine therapy for thyroid cancer is the oldest and best-known example of this strategy. The thyroid gland preferentially absorbs iodine, so giving a patient radioactive iodine delivers a lethal dose of radiation specifically to thyroid tissue while largely sparing the rest of the body.17PubMed Central. Theranostics in nuclear medicine practice The same diagnostic-then-therapeutic logic has since expanded to other cancers, including neuroendocrine tumors and prostate cancer, using different targeting molecules.
Combining Radiation with Immunotherapy
One of the more exciting developments in radiation oncology is the growing evidence that radiation can prime the immune system to attack cancer at sites far from the irradiated tumor. This phenomenon, known as the abscopal effect, was considered a rare curiosity for decades. The idea is that when radiation kills tumor cells, it spills their internal contents, including proteins that the immune system can learn to recognize as foreign. If the immune response is strong enough, it may hunt down and destroy cancer cells in distant parts of the body that were never directly irradiated.18PubMed Central. Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
The abscopal effect remained largely anecdotal until the arrival of immune checkpoint inhibitors, drugs that release the brakes on the immune system’s ability to attack cancer. Combining radiation with these drugs has substantially increased the likelihood of triggering abscopal responses. Radiation promotes the release of tumor-associated antigens and danger signals, activates the cells that present those signals to the immune system, and primes tumor-specific immune cells. Checkpoint inhibitors then sustain that immune attack and prevent the tumor from shutting it back down.19PubMed Central. Harnessing the abscopal effect: mechanistic insights and therapeutic strategies for systemic cancer immunotherapy Clinical trials are actively investigating the best radiation dose, fractionation schedule, and timing relative to immunotherapy to maximize this effect. The approach is still far from routine, but it represents a fundamental shift in thinking: radiation may not just be a local weapon but a trigger for whole-body cancer immunity.
Artificial Intelligence in Treatment Planning
Planning a Gamma Knife treatment involves deciding where to aim each beam, how long to leave it on, and how to shape the overall dose so it conforms tightly to the tumor while dropping off steeply around healthy tissue. Historically, this has been a labor-intensive process requiring experienced physicists to manually adjust dozens of parameters. Artificial intelligence is beginning to change that.
Machine learning models can now segment tumors and critical nearby structures from MRI scans with high accuracy, reducing the time and variability inherent in manual contouring.20PubMed Central. Utility of Artificial Intelligence in Stereotactic Radiosurgery for Vestibular Schwannomas: A Systematic Review Beyond image segmentation, knowledge-based planning systems can automatically select the placement of treatment isocenters, the focal points where beams converge, and optimize the dose distribution. One recent system achieved conformity comparable to manually planned treatments while producing a sharper dose falloff, meaning healthy tissue adjacent to the tumor received less unnecessary radiation.21PubMed Central. Gamma knife knowledge‐based planning with isocenter selection These tools do not replace the physicist or physician, but they can speed up the planning process and provide a consistent quality baseline, which is particularly valuable at centers that treat fewer cases and may have less experience with complex plans.
FLASH Radiotherapy
Most radiation therapy delivers its dose over several minutes per session. FLASH radiotherapy flips that paradigm by delivering the entire dose in a fraction of a second, at dose rates hundreds of times higher than conventional treatment. The striking finding from preclinical research is that this ultra-fast delivery appears to spare healthy tissues from damage far more than conventional delivery does, while killing tumor cells just as effectively.22PubMed Central. FLASH radiotherapy: an emerging approach in radiation therapy The protective effect on normal tissue has been confirmed across multiple organ systems and animal models.23PubMed Central. Clinical translation of ultra-high dose rate flash radiotherapy: Opportunities, challenges, and prospects
Why tumor cells and healthy cells respond differently to the same dose delivered at ultra-high speed is still being worked out. Leading hypotheses involve differences in oxygen consumption, DNA repair capacity, and immune-cell behavior at the two dose rates. Animal studies using clinically relevant tumor models have confirmed that the tumor-killing effect is maintained even when specific parameters of the ultra-fast delivery are varied.24PubMed. Redefining FLASH Radiation Therapy: The Impact of Mean Dose Rate and Dose Per Pulse in the Gastrointestinal Tract Translating FLASH into routine clinical use faces significant engineering challenges: current hospital-grade machines were not designed to produce the required dose rates, and verifying the dose delivered in milliseconds requires entirely new measurement tools. A handful of early human trials are underway, but FLASH remains years from widespread adoption. If the preclinical promise holds, it could represent the biggest leap in radiation therapy’s therapeutic ratio since the introduction of stereotactic techniques.